Free Communications - Vaccines 2

10:15 AM • FC 08-01 • Type-specific data on human papillomavirus infection in oropharyngeal squamous cell carcinoma in the Asia-Pacific Region > T. Tidiane Ndao 10:26 AM • FC 08-02 • End of study results of a 2 year multicountry phase IV randomized comparative study of immunogenicity and safety of the AS04-HPV-16/18 vaccine and the HPV-6/11/16/18 vaccine in HIV-positive female subjects aged 15-25 years > N. Naveen Karkada 10:37 AM • FC 08-03 • Long-term humoral response against non-vaccine oncogenic types HPV-31 and HPV-45 elicited by the HPV-16/18 vaccine in girls aged 10-14 years: 10-year follow-up data > N. Nicolas Folschweiller 10:48 AM • FC 08-04 • Systematic literature review of neutralizing antibody immune responses to non-vaccine high-risk HPV types induced by the bivalent and the quadrivalent vaccineses > A. Alfred Saah 10:59 AM • FC 08-05 • Epidemiologic impact of a gender-neutral nonavalent HPV vaccination programme in comparison to the current gender-neutral quadrivalent HPV vaccination programme in Switzerland > A. André B. Kind 11:10 AM • FC 08-06 • Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: post-HOC analysis of a community randomized clinical trial > P. Penelope Gray 11:21 AM • FC 08-07 • Bivalent HPV vaccine effectiveness correlates with phylogenetic distance towards vaccine types 16 and 18 > J. Johannes Bogaards 11:32 AM • Fc 08-08 • Health impact and cost effectiveness of implementing gender-neutral nonavalent vaccination in Flanders, Belgium > B. Barbara Merckx